501692-31-5 Usage
Molecular structure
A complex organic molecule with a tetrahydro-1,2,5-benzothiadiazepine core.
Carboxylic acid
Contains a carboxylic acid group, which can form hydrogen bonds and participate in various chemical reactions.
Hydroxybenzyl group
Contains a hydroxybenzyl group, which can also form hydrogen bonds and may contribute to the compound's biological activity.
Carbamoylmethoxy side chain
Features a carbamoylmethoxy side chain, which can interact with other molecules and may play a role in the compound's pharmaceutical applications.
Butyl substituents
Has two butyl groups attached, which can influence the compound's lipophilicity and solubility in biological systems.
Phenyl substituent
Contains a phenyl group, which can contribute to the compound's stability and may also play a role in its biological activity.
Pharmaceutical applications
Has potential pharmaceutical applications, likely as a therapeutic agent due to its intricate structure.
Biological activity
May possess biological activity that relates to its molecular design, which could be further explored for potential therapeutic uses.
Further research
Requires additional research and study to fully understand the properties and potential uses of this chemical compound.
Check Digit Verification of cas no
The CAS Registry Mumber 501692-31-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,0,1,6,9 and 2 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 501692-31:
(8*5)+(7*0)+(6*1)+(5*6)+(4*9)+(3*2)+(2*3)+(1*1)=125
125 % 10 = 5
So 501692-31-5 is a valid CAS Registry Number.
501692-31-5Relevant academic research and scientific papers
BENZOTHIAZEPINE AND BENZOTHIADIAZEPINE DERIVATIVES WITH ILEAL BILE ACID TRANSPORT (IBAT) INHIBITORY ACTIVITY FOR THE TREATMENT HYPERLIPIDAEMIA
-
Paragraph 0158, (2018/01/13)
The present invention relates to compounds of formula (I) wherein Rv, R1, R2, Rx, Ry, M, Rz, v, R3, R4, R5 and R6 are as defined within; pharmace
Bile Acid Recycling Inhibitors for Treatment of Hypercholemia and Cholestatic Liver Disease
-
, (2013/05/09)
Provided herein are methods of treating or ameliorating hypercholemia or a cholestatic liver disease by administering to an individual in need thereof a therapeutically effective amount of an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI)
CHEMICAL COMPOUNDS
-
Page/Page column 56, (2008/06/13)
The present invention relates to compounds of formula (I): wherein Rv,R1, R2, RX, RY, R3, R4, R5, R6, RZ and v are as defined within; pharmaceuti
